Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Incannex Healthcare (IXHL) Cash & Equivalents (2020 - 2025)

Incannex Healthcare's Cash & Equivalents history spans 5 years, with the latest figure at $68.9 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents rose 3184.08% year-over-year to $68.9 million; the TTM value through Dec 2025 reached $68.9 million, up 3184.08%, while the annual FY2025 figure was $15.0 million, 154.24% up from the prior year.
  • Cash & Equivalents for Q4 2025 was $68.9 million at Incannex Healthcare, down from $73.3 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $73.3 million in Q3 2025 and bottomed at $2.1 million in Q4 2024.
  • The 4-year median for Cash & Equivalents is $9.2 million (2021), against an average of $20.8 million.
  • The largest annual shift saw Cash & Equivalents crashed 85.58% in 2024 before it skyrocketed 3184.08% in 2025.
  • A 4-year view of Cash & Equivalents shows it stood at $9.1 million in 2021, then skyrocketed by 59.52% to $14.6 million in 2023, then plummeted by 85.58% to $2.1 million in 2024, then surged by 3184.08% to $68.9 million in 2025.
  • Per Business Quant, the three most recent readings for IXHL's Cash & Equivalents are $68.9 million (Q4 2025), $73.3 million (Q3 2025), and $15.0 million (Q2 2025).